AstraZeneca PLC(AZN) Stock Research - Grey Stern Research

AstraZeneca PLC (AZN) Stock Analysis

$66.70 (-1.99%)

AZN Financial Performance


Use the table below to view AstraZeneca PLC's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $68.05 -
52 Week Low $60.47 -
52 Week High $87.68 -
Market Cap $211.0 Billion 5/12
Gross Margin 77% 4/12
Profit Margin 11% 8/12
EBITDA margin 30% 8/12
Q3 - 2024 Revenue $13.6 Billion 6/12
Q3 - 2024 Earnings $1.4 Billion 8/12
Q3 - 2024 Free Cash Flow $2.0 Billion 8/12
Trailing 4 Quarters Revenue $51.2 Billion 6/12
Trailing 4 Quarters Earnings $6.5 Billion 6/12
Quarterly Earnings Growth 4% 7/12
Annual Earnings Growth -5% 6/12
Quarterly Revenue Growth 18% 5/12
Annual Revenue Growth 12% 5/12
Cash On Hand $4.8 Billion 7/12
Short Term Debt $1.6 Billion 9/12
Long Term Debt $30.0 Billion 6/12

AstraZeneca PLC Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare AstraZeneca PLC's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 32.49 6/12
PS 4.12 7/12
PB 5.17 6/12
PC 43.98 3/12
Liabilities to Equity 1.57 7/12
ROA 0.06 6/12
ROE 0.16 8/12
Current Ratio 1.64 4/12
Quick Ratio 0.08 8/12
Long Term Debt to Equity 0.74 7/12
Debt to Equity 0.78 7/12
Burn Rate 29.40 1/12
Cash to Cap 0.02 8/12
CCR 1.42 5/12
EV to EBITDA 57.96 5/12
EV to Revenue 4.64 4/12

Company Details

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

CEO: Mr. Pascal Soriot M.B.A.

Website: https://www.astrazeneca.com

Address: 1 Francis Crick Avenue Cambridge,

Exchange: NASDAQ Global Select

Industry: Drug Manufacturers—General

AstraZeneca PLC Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to AstraZeneca PLC. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $144.8 Billion
Bristol-Myers Squibb Company BMY $119.0 Billion
Gilead Sciences, Inc. GILD $115.3 Billion
AbbVie Inc. ABBV $320.7 Billion
Merck & Co., Inc. MRK $257.6 Billion
Johnson & Johnson JNJ $366.8 Billion
GSK plc GSK $71.2 Billion
Amgen Inc. AMGN $149.6 Billion
Eli Lilly and Company LLY $772.1 Billion
Novartis AG NVS $204.6 Billion
Sanofi SNY $120.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
AZN Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 13.6 Billion $1.4 Billion
Q2 2024 $ 12.9 Billion $1.9 Billion
Q1 2024 $ 12.7 Billion $2.2 Billion
Q4 2023 $ 12.0 Billion $960.0 Million
Q3 2023 $ 11.5 Billion $1.4 Billion
Q2 2023 $ 11.4 Billion $1.8 Billion
Q1 2023 $ 10.9 Billion $1.8 Billion
Q4 2022 $ 11.2 Billion $901.0 Million

View All

AZN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $4.8 Billion $104.9 Billion $31.6 Billion $40.8 Billion
Q2 2024 $6.9 Billion $104.3 Billion $33.5 Billion $39.6 Billion
Q1 2024 $7.8 Billion $102.3 Billion $34.6 Billion $37.5 Billion
Q4 2023 $5.8 Billion $101.1 Billion $28.6 Billion $39.2 Billion
Q3 2023 $4.9 Billion $96.1 Billion $28.6 Billion $37.2 Billion
Q2 2023 $5.7 Billion $96.5 Billion $29.8 Billion $37.4 Billion
Q1 2023 $6.2 Billion $96.7 Billion $31.5 Billion $35.8 Billion
Q4 2022 $6.2 Billion $96.5 Billion $29.2 Billion $37.0 Billion

View All

AZN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $2.0 Billion -$1.4 Billion -$2.2 Billion
Q2 2024 $2.5 Billion -$668.0 Million -$925.0 Million
Q1 2024 $974.0 Million -$1.6 Billion $2.0 Billion
Q4 2023 $1.4 Billion -$946.0 Million $1.0 Billion
Q3 2023 $2.2 Billion -$879.0 Million -$852.0 Million
Q2 2023 $1.2 Billion -$483.0 Million -$357.0 Million
Q1 2023 $1.7 Billion -$1.5 Billion -$155.0 Million
Q4 2022 $1.8 Billion -$554.0 Million $1.8 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions